9478cb458d
- Source: inbox/queue/2026-05-05-pmc12694361-glp1-appetite-eating-disorders-systematic-review.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 5 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
33 lines
3.7 KiB
Markdown
33 lines
3.7 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: The evidence base for GLP-1 effects in restrictive eating disorders is entirely theoretical and mechanistic with no clinical trial data, creating a regulatory and clinical knowledge gap
|
|
confidence: proven
|
|
source: MDPI Nutrients review confirming 'extremely limited' AN evidence; VigiBase aROR 4.17-6.80
|
|
created: 2026-05-04
|
|
title: No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
|
|
agent: vida
|
|
sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md
|
|
scope: structural
|
|
sourcer: MDPI Nutrients
|
|
supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
|
|
related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
|
|
---
|
|
|
|
# No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
|
|
|
|
This review explicitly confirms that evidence for GLP-1 receptor agonists in anorexia nervosa (AN) is 'extremely limited' with theoretical risks rather than empirical data. The paper states that risks for restrictive eating disorders include 'appetite suppression masking restrictive behaviors, compulsive reliance on medication for control, reinforcement of maladaptive food rules' but provides no RCT citations for these outcomes. This creates a critical evidence gap: pharmacovigilance systems show elevated eating disorder risk (VigiBase aROR 4.17-6.80), clinical guidelines recommend pre-treatment eating disorder screening, yet no prospective trials have tested GLP-1 safety or efficacy in patients with restrictive eating disorder histories. The absence of trial evidence means that current prescribing occurs without subtype-specific risk stratification. The review notes that benefits for BED (reduced binge episodes) 'may not persist long-term,' suggesting that even for the eating disorder subtype with positive theoretical rationale, durability is uncertain. This evidence vacuum is particularly concerning given that the review recommends 'rigorous monitoring until long-term safety in diverse populations established' while acknowledging that such monitoring infrastructure does not currently exist in standard prescribing practice.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** PMC/Journal of Clinical Medicine systematic review, 2025
|
|
|
|
Review confirms 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders, while simultaneously documenting case evidence and calling for longer-term follow-up studies (up to 5 years) to detect delayed ED symptom onset.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** PMC12694361 systematic review
|
|
|
|
Systematic review (October 2025, MDPI Nutrients) provides strongest current evidence synthesis: 'To date, no clinical evidence links GLP-1RA use to the onset or worsening of AN.' Evidence quality characterized as 'low-to-moderate confidence throughout' with restrictive ED evidence 'scarce and inconclusive.' Most studies are 'short-term, narrowly sampled, and methodologically limited.'
|